Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610085 · ClinicalTrials.gov registry record · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
A Phase 2 study of Hypoxic Ischemic Encephalopathy and Neonatal Encephalopathy, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 5
- Study locations
NCT05610085 is a Phase 2 study of Hypoxic Ischemic Encephalopathy and Neonatal Encephalopathy that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 133 participants, above the 73-participant average among 13 other Hypoxic Ischemic Encephalopathy trials with a reported enrollment target (82% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT05610085, a Phase 2 study of Hypoxic Ischemic Encephalopathy and Neonatal Encephalopathy, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Infants recognized as having neonatal seizures or as being at risk of developing seizures will be recruited and started on continuous video EEG monitoring (CEEG). Eligibility will be confirmed and consent will be obtained. In the first 2 phases of the study, neurologists will identify neonates with mild-moderate seizure burden (less than 8 minutes cumulative seizure activity per hour), appropriate for study with LEV, and exclude patients with higher seizure burden where treatment with PHB is more appropriate. Phase 3 of the dose escalation will only proceed if additional efficacy of LEV has been demonstrated in phases 1 and 2. In Phase 3 we will recruit neonates with seizures of greater severity up to 30 minute seizure burden/hour. This will make the final results of study more generalizable. If seizures are confirmed, enrolled subjects will receive 60mg/kg of LEV. Subjects whose seizures persist or recur 15 minutes after the first infusion is complete, subjects will then be randomized in the dose escalation study. Patients in the dose escalation study will be randomly assigned to receive either higher dose LEV or treatment with the control drug PHB in a 3:1 allocation ratio, stratified by site. Funding Source- FDA OOPD
Conditions Studied
Interventions
- DRUG Levetiracetam Injection
- DRUG Phenobarbital Sodium Injection
Study Locations (5)
Auckland
- Auckland City Hospital - Auckland
- Middlemore Hospital - Auckland
California
- University of California, San Diego - San Diego
Minnesota
- University of Minnesota - Minneapolis
Wellington Region
- Capital and Coast District Health Board, Te Whatu Ora, Health New Zealand - Wellington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610085
The ClinicalTrials.gov registry entry for NCT05610085 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 13 other Hypoxic Ischemic Encephalopathy trials with a reported enrollment target (82% higher). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hypoxic Ischemic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which Levetiracetam Injection is the first listed.
NCT05610085 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Auckland, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05610085 about?
NCT05610085 is a clinical study titled "A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures". The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation...
What is the current status of trial NCT05610085?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2023-03-24. Estimated completion is 2027-12-31.
What conditions does trial NCT05610085 study?
This clinical trial studies the following conditions: Hypoxic Ischemic Encephalopathy, Neonatal Encephalopathy, Neonatal Seizure, Seizure Newborn.
What interventions are being tested in trial NCT05610085?
The interventions under investigation include: Levetiracetam Injection (DRUG), Phenobarbital Sodium Injection (DRUG).
Who is sponsoring clinical trial NCT05610085?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610085 being conducted?
This trial has 5 study locations across California, Minnesota, Auckland, Wellington Region. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoxic Ischemic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
RECRUITING · Phase 2
-
Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)
COMPLETED · Phase 2
-
The HIEnome Study: Genome Sequencing for Perinatal HIE
RECRUITING · NA
-
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
RECRUITING · Early Phase 1
-
Dose Optimization of Caffeine for HIE
RECRUITING · Phase 1
-
Healthy Little Eyes
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.